» Articles » PMID: 31819184

Metabolic Response Patterns in Brain Microdialysis Fluids and Serum During Interstitial Cisplatin Treatment of High-grade Glioma

Overview
Journal Br J Cancer
Specialty Oncology
Date 2019 Dec 11
PMID 31819184
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High-grade gliomas are associated with poor prognosis. Tumour heterogeneity and invasiveness create challenges for effective treatment and use of systemically administrated drugs. Furthermore, lack of functional predictive response-assays based on drug efficacy complicates evaluation of early treatment responses.

Methods: We used microdialysis to deliver cisplatin into the tumour and to monitor levels of metabolic compounds present in the tumour and non-malignant brain tissue adjacent to tumour, before and during treatment. In parallel, we collected serum samples and used multivariate statistics to analyse the metabolic effects.

Results: We found distinct metabolic patterns in the extracellular fluids from tumour compared to non-malignant brain tissue, including high concentrations of a wide range of amino acids, amino acid derivatives and reduced levels of monosaccharides and purine nucleosides. We found that locoregional cisplatin delivery had a strong metabolic effect at the tumour site, resulting in substantial release of glutamic acid, phosphate, and spermidine and a reduction of cysteine levels. In addition, patients with long-time survival displayed different treatment response patterns in both tumour and serum. Longer survival was associated with low tumour levels of lactic acid, glyceric acid, ketoses, creatinine and cysteine. Patients with longer survival displayed lower serum levels of ketohexoses, fatty acid methyl esters, glycerol-3-phosphate and alpha-tocopherol, while elevated phosphate levels were seen in both tumour and serum during treatment.

Conclusion: We highlight distinct metabolic patterns associated with high-grade tumour metabolism, and responses to cytotoxic cisplatin treatment.

Citing Articles

Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance.

Srivastava S, Anbiaee R, Houshyari M, Laxmi , Sridhar S, Ashique S Cancer Cell Int. 2025; 25(1):89.

PMID: 40082966 PMC: 11908050. DOI: 10.1186/s12935-025-03721-1.


Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient's outcomes.

Sanchez-Castillo A, Kampen K Discov Oncol. 2024; 15(1):652.

PMID: 39538085 PMC: 11561223. DOI: 10.1007/s12672-024-01544-6.


Blood based metabolic markers of glioma from pre-diagnosis to surgery.

Loding S, Antti H, Sjoberg R, Melin B, Bjorkblom B Sci Rep. 2024; 14(1):20680.

PMID: 39237693 PMC: 11377417. DOI: 10.1038/s41598-024-71375-6.


An Injury-like Signature of the Extracellular Glioma Metabolome.

Ha Y, Rajani K, Riviere-Cazaux C, Rahman M, Olson I, Gharibi Loron A Cancers (Basel). 2024; 16(15).

PMID: 39123433 PMC: 11311774. DOI: 10.3390/cancers16152705.


LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancer.

Yan R, Liu D, Guo H, Liu M, Lv D, Bjorkblom B Cell Death Dis. 2024; 15(6):436.

PMID: 38902268 PMC: 11190201. DOI: 10.1038/s41419-024-06836-x.


References
1.
Segal E, Le Pecq J . Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets. Cancer Res. 1985; 45(2):492-8. View

2.
Muguruma K, Nakata B, Yanagawa K, Nitta A, Yashiro M, Onoda N . Caspase-1 activity as a possible predictor of apoptosis induced by cisplatin in gastric cancer cells. Int J Mol Med. 2000; 6(5):553-7. DOI: 10.3892/ijmm.6.5.553. View